Parkin Antibody - N-terminal region (OAAB16691)

Catalog No: OAAB16691

Size:400ul

Western blot analysis of anti-PARK2 (Parkin) Antibody (N-term) (Cat.#OAAB16691) in NCI-H460 cell line lysates (35ug/lane). PARK2 (Parkin)(arrow) was detected using the purified Pab.

Parkin Antibody (N-term) (OAAB16691)immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of Parkin Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

Confocal immunofluorescent analysis of Parkin Antibody (N-term)(Cat#OAAB16691) with NCI-H460 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).

Parkin Antibody (N-term) (Cat. #OAAB16691) flow cytometric analysis of NCI-H460 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Product Info

• Predicted Species Reactivity: Human
• Product Format: Liquid. PBS with 0.09% (W/V) sodium azide.
• Clonality: Polyclonal
• Isotype: Ig
• Host: Rabbit
• Application: WB, FC, IF, IHC-P
• Additional Information: Function: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'- linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene
  
  Cellular Location: Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Note=Mainly localizes in the cytosol Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent
  Tissue Location: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum (at protein level)
• Reconstitution and Storage: Maintain refrigerated at 2-8C for up to 2 weeks. For long term storage store at -20C in small aliquots to prevent freeze-thaw cycles.
• Immunogen: This Parkin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 111-140 amino acids from the N-terminal region of human Parkin.
• Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
• Concentration: Approximately 0.5mg/ml. Actual concentration varies with each lot.
• Sample Type Confirmation:

  PARK2 is strongly supported by BioGPS gene expression data to be expressed in NCI-H460

• Intended Use: Parkin Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.
• Application Info: WB: 1:250~1:1000
  FC: 1:10~50
  IF: 1:10~50
  IHC-P: 1:10~50

Target Info

• Gene Symbol: PARK2
• Alias Symbols: PDJ, AR-JP, LPRS2, PARK2
• NCBI Gene Id: 5071
• Protein Name: E3 ubiquitin-protein ligase parkin
• Description of Target: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known; however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function.
• Uniprot ID: O60260
• Protein Accession #: NP_004553.2
• Molecular Weight: 51641 Da